Abstract: Disclosed herein is a system for facilitating administration of a pharmaceutical product. Accordingly, the system may include at least one sensor, a storage device, a processing device, and a Mobile Administration Interlocking Device (MAID). Further, the at least one sensor may be disposed on body of a user. Further, the at least one sensor may be configured for generating at least one physiological data associated with the body. Further, the storage device may be configured for storing at least one dosage data. Further, the at least one dosage data may be prescribed by a medical professional. Further, the processing device may be communicatively coupled with the at least one sensor. Further, the processing device may be communicatively coupled with the storage device. Further, the MAID may be configured for provisioning the pharmaceutical product to the user. Further, the MAID may be communicatively coupled with the processing device.

Abstract: The present disclosure is directed to a natural-based liquid composition for use with electronic vaporizing devices. The present disclosure is also directed to electronic vaporizing devices for using such composition. In one embodiment, the liquid compositions are water-based and are substantially free of propylene glycol and vegetable glycerin. In a preferred embodiment, the compositions may be augmented to include additives such as medicines, wellness elements, supplements, recreational elements, and natural elements performing the role of emulsifiers. The present disclosure is also directed to electronic vaporizing devices for vaporizing a natural-based liquid composition. The electronic vaporizing device may include the functionality to create specified or custom mixtures of a vaporizable material for the vaporizing thereof.

Abstract: Disclosed is an apparatus for measuring bio signals. The apparatus for measuring bio signals includes: a sensor module configured to include a needle sensor to be inserted into the skin; and a main body to which the sensor module is separably coupled, and which is configured to include a controller controlling the sensor module to measure a bio signal through the needle sensor, once the sensor module is coupled.

Abstract: Provided are a storage container, a microneedle unit, a storage container group, and a method of producing a microneedle unit that enable protection of a microneedle array before puncture and realization of a puncturing property of the microneedle array using a simple member. The storage container, which stores a microneedle array including a sheet having a first surface and a second surface that oppose each other and a plurality of needles arranged on the first surface of the sheet, includes a first member having an edge portion that defines a second opening and a second member having a depression, in which the microneedle array is stored by superimposing the second member on the first member, and the second member and the first member are deformed by applying a force to the second member in a state in which the second member is superimposed on the first member, and the needles of the microneedle array are allowed to protrude from the first member to puncture a skin.

Abstract: A method of atraumatic medication pellet delivery using an atraumatic trocar apparatus is described. The atraumatic trocar apparatus includes a cannula and an obturator. The method includes receiving the obturator by the cannula, wherein the obturator passes through the interior passage and exits through the anterior cannula opening so that the obturator anterior rounded tip extends past the anterior cannula end and at least one opening proximate to the anterior rounded tip also extends past the anterior cannula end. The method includes inserting the atraumatic trocar through an incision into subcutaneous tissue along an insertion path to an insertion length. Additionally, the method includes inserting one or more medication pellet into the medication slot of the inserted cannula and delivering the medication pellet(s) through the interior passage of the cannula to a subcutaneous delivery site by inserting the obturator into the posterior opening of the cannula.

Abstract: Certain embodiments comprise administering a residence structure to a subject (e.g., a patient) such that the residence structure is retained at a location internal to the subject for a particular amount of time (e.g., at least about 24 hours) before being released. In certain embodiments, the structure has a modular design, combining a material configured for controlled release of therapeutic, diagnostic, and/or enhancement agents with a structural material necessary for gastric residence but configured for controlled and/or tunable degradation/dissolution to determine the time at which retention shape integrity is lost and the structure passes out of the gastric cavity. For example, in certain embodiments, the residence structure comprises a first elastic component, a second component configured to release an active substance, and, optionally, a linker. In some such embodiments, the linker may be configured to degrade.

Abstract: An intravenous (IV) fluid delivery system include an IV bag and a fluid delivery device. The IV bag is made of many fluidic channels that keep the fluid distributed across the bag such that the bag may be easily and comfortably wrapped around the arm and shoulder of a person. The fluid delivery device includes a processor controlled electromechanical delivery mechanism that controls a positive displacement pump. The pump moves the fluid into a tube and a needle that is connected to a person's vein. The processor repeatedly turns the pump on or off to gradually transfer the fluid from the IV bag into the person's vein. The processor controls the granularity of the fluid delivery, where the fluid may be administered in a fluid delivery period, the fluid delivery may then be stopped in a subsequent fluid stoppage period, followed by other fluid delivery periods.

Abstract: A wearable injector for automated delivery of biologic drugs that solves the problem of high volume and high viscosity drug administration by providing a device that can be worn by the patient through use of an adhesive patch to deliver the medication slowly over extended periods of time.

Abstract: Infusion systems, infusion devices, and related operating methods are provided. An exemplary method of operating an infusion device to deliver a bolus amount of fluid influencing a physiological condition in a body of a user involves identifying, based on measurement values for the physiological condition, a residual value for the physiological condition resulting from the bolus amount of the fluid and determining an updated ratio for a subsequent bolus by adjusting an initial ratio influencing the bolus amount to compensate for the residual value. The updated ratio may be stored in a data storage element for use in determining a subsequent bolus amount in lieu of the initial ratio value.

Abstract: A surgical stapling device includes a tool assembly that has a staple cartridge that includes a perfluorocarbon (hereinafter “PFC”) solution that is injected into tissue when the surgical stapling device is fired to improve oxygenation of tissue being treated. In aspects of the disclosure, the tool assembly of the surgical stapling device includes a staple cartridge that has staples that are supported on pushers and an actuation sled that is movable through the staple cartridge into engagement with the pushers to eject staples from the staple cartridge. In certain aspects of the disclosure, the PFC solution is contained within the pushers of a staple cartridge of the tool assembly and the actuation sled includes protrusions that engage the pushers to eject the PFC solution from the pushers when the stapling device is fired.

Abstract: Methods, compositions, and devices for enhancing transdermal delivery of large agents.

Abstract: An implantable device contains a drug or biosensing compound, protected from the external environment within a human body by several barriers which are broken upon activation of the device through electrothermal, chemical, and mechanical processes. The device allows accurate and repeated dosing within a human body, thus reducing the number of implantation procedures required. This device extends the lifetime of a biosensor, reducing the number of implantation procedures required.

Abstract: A system and method for identifying a stimulation location on a nerve is disclosed. The system includes an image-based navigation interface used to facilitate advancing a stimulation element within a patient body toward a target nerve stimulation site. Using the system one determines, separately for each potential target nerve stimulation site, a neuromuscular response of muscles produced upon applying a stimulation signal at the respective separate potential target stimulation sites. The image-based navigation interface is configured to display a graphic identification of which muscles were activated for each respective potential target nerve stimulation site upon applying the stimulation signal.

Abstract: A method of securing an antenna assembly to a wearable article includes positioning a template carrying a first antenna at a desired position on the wearable article worn on a body of a patient. The desired position is in proximity to a wireless tissue stimulator implanted within the body. The method further includes marking a location of the desired position of the template against the wearable article, securing a first attachment feature to the wearable article at a mark located at the desired position, and attaching the antenna assembly to the wearable article at the first attachment feature. The antenna assembly includes a second antenna configured to send a signal carrying electrical energy to the wireless tissue stimulator and a housing carrying the second antenna. The housing includes a second attachment feature configured to engage the first attachment feature for positioning the second antenna adjacent the body.

Abstract: Ingestible devices with a relatively large payload volume or sample volume, as well as related components, systems and methods, are disclosed.

Abstract: A medicament delivery device includes a device housing for placing on the skin of a patient, the housing including a needle aperture; a needle for injecting a medicament, the needle arranged to pass through the needle aperture; and sensors configured to provide a signal when the housing is placed on the skin of the patient. The sensors are arranged around the needle aperture.

Abstract: A blood glucose control system is configured to modify therapy provided to a subject. The system can cause first therapy to be delivered by the blood glucose control system to a subject during a first therapy period. The first therapy can be delivered based at least in part on a first value of a control parameter used by a control algorithm to generate a dose control signal. The system can determine a first effect corresponding at least in part to the first therapy and autonomously generate a second value of the control parameter. The system can cause second therapy to be delivered by the blood glucose control system to the subject during a second therapy period, wherein the second therapy is delivered based at least in part on the second value of the control parameter.

Abstract: A tool has an outer assembly, which includes a deployment tube, extending around, and moveable with respect to an inner assembly of the tool; the inner assembly includes a single pull wire and a distal member configured to engage an end of an implantable medical device. The deployment tube includes an articulating segment located just proximal to an enlarged distal-most portion, which contains the device and the distal member. Relatively soft and stiff sections of a composite sidewall define the articulating segment and extend alongside one another, such that, when the pull wire is actuated, the composite sidewall causes bending of the segment in two directions. A handle assembly of the tool includes a control member for the pull wire, and may further include a flushing subassembly that has a connector port located at an end of the handle assembly that is opposite a proximal port of the handle.

Abstract: An embodiment of the invention is a shape memory polymer (SMP) foam designed to recover its original shape through exposure to a solvent. Thermo-responsive SMPs are polymers designed to maintain a programmed secondary shape until heated above their transition temperature, upon which the polymer recovers its original, or primary, shape. The thermo-responsive SMP foam is programmed to its secondary shape prior to use, typically compression of the foam to a small volume, and remains in this programmed shape until exposed to a selected solvent such as dimethyl sulfoxide or ethyl alcohol. Upon exposure to the solvent, the transition temperature of the SMP foam decreases below the temperature of the environment and the SMP foam actuates to its primary shape. The SMP foam is tailored to actuate upon exposure to specific solvents while minimizing or preventing actuation when exposed to water or other solvents.

Abstract: A method includes providing a medication delivery vehicle comprising a reservoir with a seal formed thereon and a cantilevered beam micro-machined from a layer of material and coupled to the reservoir, the cantilevered beam comprising a tip for puncturing the seal, applying an electric field to the cantilevered beam that impels the tip forward and causes the tip to break through the seal of the reservoir, and changing the electric field to impel the micro-machined tip backward and thereby release a medication from the reservoir. A computer program product and computer system corresponding to the method are also disclosed.

Abstract: An ingestible pill is provided that includes an enteric coating and a medication-delivery device, which includes (a) a patch having upper and lower surfaces that face in generally opposite directions, and (b) needles. The patch is disposed within the enteric coating, folded so as to define one or more creases, which define respective inner and outer crease sides, wherein at least 50% of the needles are coupled to the patch along the inner crease sides. The patch is configured to assume, after the enteric coating dissolves, an expanded shape, in which the patch has an outer perimeter. Other embodiments are also described.

Abstract: A blood glucose control system is configured to modify therapy provided to a subject. The system can cause first therapy to be delivered by the blood glucose control system to a subject during a first therapy period. The first therapy can be delivered based at least in part on a first value of a control parameter used by a control algorithm to generate a dose control signal. The system can determine a first effect corresponding at least in part to the first therapy and autonomously generate a second value of the control parameter. The system can cause second therapy to be delivered by the blood glucose control system to the subject during a second therapy period, wherein the second therapy is delivered based at least in part on the second value of the control parameter.

Abstract: An inner ear fluid circulation system includes an implantable circulation pump that has a pump inlet and a pump outlet both in fluid communication with inner ear fluid of an implanted patient. The circulation pump is configured to drive the inner ear fluid in from the pump inlet and out through the pump outlet. A pump controller is coupled to the circulation pump and one or more sensing elements for measurement of one or more fluid conditions within the inner ear of the implanted patient, and is configured to control operation of the circulation pump as a function of the measured one or more fluid conditions. Also disclosed is a cochlear implant arrangement and a vestibular implant arrangement comprising such a fluid circulation system.

Abstract: A blood glucose control system is configured to modify therapy provide to a subject and determine whether the modified therapy results in a statistically significant improvement in glycemic control. The system obtains glycemic control information resulting from delivery of first therapy using a first value of a control parameter and determines a first effect corresponding to the first therapy. The control parameter is set to a second value that differs from the first value. The system obtains glycemic control information resulting from the delivery of the second therapy using the second value of the control parameter and determines a second effect corresponding to the second therapy. The system can perform a comparative assessment and determine whether the second value for the control parameter results in a statistically significant improvement in glycemic control for the subject.

Abstract: This invention relates to novel extended release pharmaceutical compositions of levetiracetam and preparations and characterizations thereof. This invention further relates to using these extended release pharmaceutical compositions of levetiracetam for the treatment of cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof.

Abstract: An intragastric balloon device including a deformable material is in an ingestible form for delivery to a stomach of a patient, expands in response to stimuli in the stomach, and degrades within a limited duration (such as 16 hours or some other value between 2 hours and 72 hours) to diminish to passable form in which remains of the intragastric balloon device are passable from the stomach. In an illustrative example, the deformable material is composed of silicone coated with parylene and encloses perfluoropentane fluid that transitions from liquid to gas due to stomach temperature to inflate the balloon in the stomach and occupy space in the stomach until a fuse of methacrylate erodes to unblock a vent conduit to permit escape of the perfluoropentane for deflating the balloon to diminish to passable form.

Abstract: A frequency sensor comprises a surface functionalized with a reactant sensitive to an analyte and a vibration detector coupled to the functional surface to detect a frequency of a fluid having the analyte and located on the functional surface during vibration thereof. The frequency sensor comprises a measurement circuitry coupled to the vibration detector to determine a frequency shift over time of the detected frequency, wherein the frequency shift corresponds to the presence of the analyte which has reacted with the reactant.

Abstract: Provided herein is an implant for delivering a hydrophobic active agent to a target tissue. The implant may include a scaffold defining a first surface and a second surface opposite the first surface, wherein the scaffold is substantially impermeable to a hydrophobic active agent, and a silicone tubing having a wall permeable to the active agent, wherein a first length of the silicone tubing is affixed to the first surface of the scaffold, wherein the two ends of the silicone tubing extend from the first surface, and wherein a path outlined by a second length of the tubing within the first length is circuitous. Also provided is a method of using the implant to locally deliver a hydrophobic active agent to a target tissue, and kits that find use in performing the present method.

Abstract: A digital biomedical device includes a substrate forming a cavity, a seal formed around the cavity, a lid coupled to the substrate by the seal, a reactive metal structure comprising a plurality of metal layers, wherein the reactive metal structure is a component of at least one of the substrate and the lid, a metal trace configured to initiate a self-propagating reaction between the plurality of metal layers of the reactive metal structure and release contents of the cavity, and a power supply configured to apply an electric current to the metal trace.

Abstract: A method of atraumatic medication pellet delivery using an atraumatic trocar apparatus is described. The atraumatic trocar apparatus includes a cannula and an obturator. The method includes receiving the obturator by the cannula, wherein the obturator passes through the interior passage and exits through the anterior cannula opening so that the obturator anterior rounded tip extends past the anterior cannula end and at least one opening proximate to the anterior rounded tip also extends past the anterior cannula end. The method includes inserting the atraumatic insertion trocar through an incision into subcutaneous tissue along an insertion path to an insertion length. Additionally, the method includes inserting one or more medication pellet into the medication slot of the inserted cannula and delivering the medication pellet(s) through the interior passage of the cannula to a subcutaneous delivery site by inserting the delivery obturator into the posterior opening of the cannula.

Abstract: An arrangement for producing a sample of body fluid from a wound opening created in a skin surface at a sampling site includes at least one skin-penetration member having a first end configured to pierce the surface of the skin, and a inner lumen in communication with the first end; at least one actuator operatively associated with the at least one skin-penetration member; and at least one catalyst device configured to cause perfusion of body fluid at the sampling site; wherein the at least one actuator is configured to locate the at least one skin-penetration member so as to obstruct the wound opening while transporting body fluid through the inner lumen. Associated methods are also described.

Abstract: The disclosure relates to a retrievable intrauterine device which includes a recess suitable for containing one or more elements selected from the group that includes an embryo, male and/or female gametes, a fertilized oocyte, a non-fertilized ovule and a combination of the elements. The recess includes an inner wall made of a biocompatible polymer, the inner wall including at least one perforated portion having perforations with dimensions of between 1 pm and 10 pm, and an outer wall covering the inner wall, the outer wall being made of a biocompatible silicone elastomer and including at least one opening opposite said at least one perforated portion of the inner wall. The use of the device relates to the preimplantation development of gametes and/or embryos.

Abstract: A method for neurological analysis and treatment is described. In one embodiment, a server sends a request to a wearable device for sensor data of a patient. The server receives sensor data from the wearable device, and sends instructions to the wearable device to present a cognitive test based on the sensor data. The server receives from the wearable device, results of the cognitive test, compares the results against a baseline, and determines an assessment of the user. A notification may be sent to the wearable device based on the assessment. A wearable device for use in the analysis and treatment is also described.

Abstract: Embodiments relate to a cannula that is provided for delivering a substance, such as a medicine (e.g., insulin) to a patient, where the cannula has reduced likelihood of kinking or occlusions when implanted in a patient. The cannula may have a reduced number of stress concentrations along its length, an angled tip and/or a curve in its length. The cannula may include other designs to reduce kinking, such as internal ribbing and/or a slit along its wall.

Abstract: A free-jet dosing system for administering a fluid into or under the skin having a micropump and a nozzle arranged on the outlet side. The micropump has an inlet and an outlet and is configured to transport a fluid from the inlet to the outlet and to generate a blocking pressure of at least 20 bar at the outlet. The nozzle is configured to output the fluid output at the outlet as a free jet at a fluid pressure so that the fluid of the free jet may be injected into the skin.

Abstract: The subject technology is embodied in a method for predicting a delivery rate of a plurality of drugs dispensed by multiple infusion pumps at a delivery point. The method includes receiving one or more operating parameters related to multiple drug pumps and a carrier fluid pump, wherein each of the drug pumps dispenses a drug, and the carrier fluid pump dispenses a carrier fluid. The method also includes determining a delivery rate of a first drug at the delivery point. This can be done by predicting time variation of a concentration of the first drug at the delivery point based on a mathematical model of a mixed flow through a fluid path that terminates at the delivery point. The mixed flow includes the drugs and the carrier fluid. The model includes the operating parameters and a plurality of flow-parameters related to the mathematical model of the mixed flow.

Abstract: Some embodiments an infusion pump system can be used to determine a user's total insulin load (TIL) that provides an accurate indication of the insulin previously delivered to the user's body which has not yet acted. In particular embodiments, the TIL can account for both the bolus deliveries and the basal deliveries that have occurred over a period of time. Such information may be useful, for example, when the infusion pump is operated in conjunction with a continuous glucose monitoring device.

Abstract: The invention is directed to recombinant probiotic bacteria, especially for use in the treatment of an inflammatory skin dysfunction, as well as a method for treating an inflammatory skin dysfunction.

Abstract: An ingestible pill is provided that includes an enteric coating and a medication-delivery device, which includes (a) a patch having upper and lower surfaces that face in generally opposite directions, and (b) needles. The patch is disposed within the enteric coating, folded so as to define one or more creases, which define respective inner and outer crease sides, wherein at least 50% of the needles are coupled to the patch along the inner crease sides. The patch is configured to assume, after the enteric coating dissolves, an expanded shape, in which the patch has an outer perimeter. Other embodiments are also described.

Abstract: A method for chip encryption includes obtaining a fuse value and a trim value of a chip and setting an encryption algorithm, setting the fuse value and the trim value as parameters of the encryption algorithm and obtaining a secret key which is unique for the chip accordingly to the encryption algorithm, and storing the fuse value, the trim value and the secret key in the chip. Since the fuse value and trim value of the chip are unique naturally, the secret key obtained from the same matrix chip for different applications or different matrix chips for the same application are different from each other, thereby increasing expenses and difficulty for crackers to crack the chip and protecting user's intellectual property perfectly.

Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Some embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. The device comprises a capsule sized to be swallowed and pass through the intestinal tract. The capsule can include at least one guide tube, one or more tissue penetrating members positioned in the guide tube, a delivery member, an actuating mechanism and a release element. The release element degrades upon exposure to various conditions in the intestine so as to release and actuate the actuating mechanism. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

Abstract: Certain embodiments according to the present invention provide sleeve devices suitable for a wide range of therapeutic uses. In accordance with certain embodiments, the therapeutic sleeve device includes a nanofiber fabric assembly, which defines a plurality of pores, and at least one layer of cells embedded in the nanofiber fabric assembly.

Abstract: The present disclosure provides for brewing apparatus, such as a disposable brewing pod, filter, beverage screen, or tea bag, treated with an oil-based solution comprising a lipid component; an emulsifier; and a pharmaceutical, holistic, or medical component. Brewing apparatus may be sprayed with a spray gun, such as a high volume low pressure spray gun, a precision bottle-top dispenser, or an automatic apparatus configured to apply an oil-based solution to the brewing apparatus. The brewing apparatus may be filled with a product to be brewed and packaged for individual use. The present disclosure additionally provides for a brewed drinkable product produced using brewing apparatus treated with an oil-based solution comprising a lipid component; an emulsifier; and a pharmaceutical, holistic, or medical component. The end product may be a hot or cold product.

Abstract: A basal hub for attaching to an infusion base is disclosed. The hub includes a fluid reservoir and pressure actuating device. A septum portion of the reservoir is configured to be opened by a flow cannula that is in fluid communication with an infusion cannula of the infusion base, when the basal hub is attached to the infusion base. The pressure actuating device applies pressure to the fluid reservoir, such that when the septum portion of the fluid reservoir is pierced by the by the flow cannula, liquid stored in the fluid reservoir is released from the fluid reservoir into the infusion cannula of the infusion base via the flow cannula. The basal hub is configured to deliver a basal dose of insulin during periods of inactivity, such as during sleep time.

Abstract: Embodiments of the present invention are directed to a liquid delivery apparatus. A non-limiting example of the apparatus includes a substrate including a cavity formed in a surface of the substrate. The apparatus can also include a membrane disposed on the surface of the substrate covering an opening of the cavity. The apparatus can also include a hydrophobic layer disposed on the membrane. The apparatus can also include a seal disposed between the membrane and the substrate, wherein the seal surrounds the opening of the cavity. The apparatus can also include an electrode layer coupled to the membrane.

Abstract: Disclosed is a system and a method for determining an injectable amount of bile required for a patient after gallbladder removal. The system comprises a receiving module, a creating module, and a determining module. The receiving module may receive a bile-flow rate, physiological parameters of a patient, and amount of fatty food in an alimentary tract of the patient. Based on these data received, the creating module may create a graph. Further, the determining module may determine a correlation between the bile-flow rate and the amount of fatty food in the alimentary tract based on the graph created. The correlation may be determined corresponding to a normal person and the patient which may be seen by two separate curves on the graph. Further, the determining module may determine an injectable amount of bile required for the patient based on the correlation.

Abstract: An atomizer includes a cartridge with a reservoir containing a fluid and a heating system configured to atomize the fluid into a vapor for inhalation. A respiratory indicator is configured to determine an inhalation period and an exhalation period of a patient using the atomizer. The atomizer then increases atomization of the vapor during the inhalation period and decreases atomization of the vapor during the exhalation period. An impedance sensor measures an amount of the fluid in the atomizer and deactivates atomization in response to an indication of a low fluid level.

Abstract: An applicator-based transdermal drug delivery system (ABTDS) for administration of drugs to a patient to treat ailments in combination with a wide range of topical formulation classes including but not limited to creams, foams, gels, lotions, and ointments is described herein. The transdermal drug delivery system utilizes an applicator that can be in various disk-like shapes and sizes, and that contain the topical formulation in a fixed area, and is applied over the skin of the patient to ensure accurate drug delivery and protect the drug from being rubbed away. Additional features of the applicator include numerous blunt spikes present on its surface that are designed to enhance rate of drug delivery.

Abstract: Disclosed is a dispensing system. The dispensing system includes a dispensing unit to dispense therapeutic fluid, and a validation mechanism to enable operation of the dispensing unit based, at least in part, on a determination of whether operation of the dispensing device is authorized.

Abstract: Disclosed is an ocular device including a first structure formed of a first material providing a first shape to the ocular device prior to positioning the ocular device on the surface of the eye, a second structure formed of a second, different material having a tubular structure and a lumen through which the first structure extends, and at least one therapeutic agent is dispersed within the second material of the second structure. The first shape of the ocular device conforms to a second, different shape after positioning the ocular device on the surface of the eye. Upon being removed from the eye, the ocular device retains the second shape or changes to a third shape different from both the first shape and the second shape. Related apparatus, systems and method are described.